Abstract
Burkitt’s lymphoma (LB) is an uncommon and aggressive subtype of non-Hodgkin’s lymphoma uncommon in adults. Three clinical variants are recognized: associated with immunodeficiency, sporadic (America) and the endemic one of equatorial Africa. We present the case of a 21-year-old man with LB whose first manifestation was the appearance of a tumor in the left maxilla and symptoms, initially treated as a dental abscess and otomastoiditis, with poor outcome mainly due to a delay in the diagnosis due to lack of consideration as an alternative differential diagnosis in immunocompetent subjects.
References
2. Molyneux EM, Rochford R, Griffin B .Burkitt’s lymphoma. Lancet. 2012 Mar 31;379(9822):1234-44. Disponible en : http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61177-X/fulltext
3. Mata C. Linfoma de Burkitt: el tumor pediátrico más frecuente en África. Acta Pediatr Esp. 2008; 66(7): 322-326.
4. Orem J, Katongole Mbidde E, De Sanjose S, Weiderpas E. Burkitt’s lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci. 2007 Sep; 7(3): 166- 175.
5. Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM. Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med. 2014 Feb 1;4(2): 1-5. Disponible en http://perspectivesinmedicine.cshlp.org/content/4/2/a014282.full.pdf+html
6. Corti M, Villafane F, Valerga M et al. Linfoma de Burkitt primario de la cavidad oral en una paciente con SIDA Reporte de un caso y revisión de la literatura . Rev Esp Cir oral maxilofac. 2015;37(1):44-47.
7. Uyanik R, Caviedes C, Rofin S et al . Inusual presentación de limfoma de Burkitt: caso clínico. Cir Esp. 2014;92(Espec Congr):946.
8. Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E et al. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood [Internet]. 2015 Jul 9 [cited 2018 Jul 31];126(2):160.6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25957391
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar
